Dominari Holdings Inc. (NASDAQ:DOMH) Sees Significant Growth in Short Interest

Dominari Holdings Inc. (NASDAQ:DOMH) saw a large growth in short interest during the month of February. As of February 15th, there was short interest totalling 952,800 shares, a growth of 232.0% from the January 31st total of 287,000 shares. Currently, 30.6% of the shares of the company are short sold. Based on an average daily volume of 1,480,000 shares, the short-interest ratio is currently 0.6 days.

Dominari Stock Performance

Shares of Dominari stock opened at $7.80 on Friday. Dominari has a 1 year low of $0.83 and a 1 year high of $13.58. The company has a market capitalization of $49.42 million, a P/E ratio of -2.02 and a beta of 1.25. The company’s fifty day moving average is $3.94 and its two-hundred day moving average is $2.49.

Dominari Announces Dividend

The company also recently announced a dividend, which will be paid on Monday, March 3rd. Stockholders of record on Monday, February 24th will be paid a $0.32 dividend. The ex-dividend date of this dividend is Monday, February 24th.

Institutional Trading of Dominari

An institutional investor recently raised its position in Dominari stock. Renaissance Technologies LLC lifted its stake in Dominari Holdings Inc. (NASDAQ:DOMH) by 20.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 56,326 shares of the company’s stock after purchasing an additional 9,400 shares during the period. Renaissance Technologies LLC owned approximately 0.89% of Dominari worth $55,000 as of its most recent SEC filing. Institutional investors own 42.48% of the company’s stock.

Dominari Company Profile

Dominari Holdings Inc, a biotechnology company, focuses on developing small-molecule anticancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia.